Huawei Joins UNESCO Global Alliance for Literacy to Step Up Talent Cultivation
28.2.2023 13:47:00 EET | Business Wire | Press release
Huawei announced it has joined the UNESCO Global Alliance for Literacy (GAL) on February 26th as part of the company’s lead up to the Mobile World Congress 2023. The announcement was made at a Digital Talent Summit co-hosted by Huawei and the UNECSO Institute for Lifelong Learning (UIL) which serves as the Secretariat of the GAL.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005765/en/
Representative from Huawei and UNESCO Institute for Lifelong Learning signs agreement (Photo: Huawei)
At the Summit, Huawei and the UIL agreed to jointly promote the use of technology to raise literacy. The two parties also signed a cooperation agreement under which Huawei will fund an expansion of the UIL’s current initiatives to enhance educators’ use of technology in developing countries. Currently, the UIL initiative operates in Bangladesh, Côte d’Ivoire, Egypt, Nigeria, and Pakistan.
Huawei is the first private company to become an associate member of the GAL and the company is excited its own goals align with the GAL’s vision of eradicating digital illiteracy in young people.
UIL Director David Atchoarena explained at the event, “Our rapidly changing world calls for concerted efforts and strong partnerships to achieve quality education and lifelong learning for all.”
Atchoarena continued, “Huawei’s expertise in the area of innovation in learning will be a great asset to the Global Alliance for Literacy. Collaborative projects such as ours will ensure that no one is left behind on this journey.”
Huawei’s own Vice President of Corporate Communications Vicky Zhang also commented, “Getting the right education is often the key to success in life. As a major player in the technology sector, Huawei feels it has a responsibility to provide technology skills in all parts of the world, trying our best to include as many people as possible.”
“We are proud to join forces with UNESCO to better deliver on this responsibility,” Zhang added.
Huawei believes digital talent is a key driver in achieving digital transformation, solid economic growth, and better quality of life. Since 2008, Huawei has offered a wide and expanding range of talent programs. Under its Seeds for the Future umbrella, Huawei provides tens of thousands of people every year with scholarships and digital training courses targeting all age groups. The company also organizes and sponsors tech competitions where students can expand their knowledge, win prizes, and make new friends.
Dr. Piti Srisangnam, Executive Director of ASEAN Foundation applauded Huawei’s contribution to the local talent community. “The ASEAN Seeds for the Future program that we launched in 2022 together with Huawei has already become a resourceful platform for hundreds of local students in ten ASEAN countries to learn ICT knowledge and have cultural exchanges,” he said.
John Omo, Secretary General of African Telecommunication Union (ATU), also emphasized on the necessity of bridging the local talent to the international community. He said, “It is critical that youth in Africa have access to global opportunities and can be a part of global conversations.”
Sen. Jorge Ramirez Marin, President of the Commission of Science and Technology of Mexico Senate also called for a global synergy. “Digital education should be a factor that brings us closer to equity, instead of aggravating inequality,” he said.
The summit concluded with a profound and interesting panel session on imagining the future of education. The panel discussion was shared by George Gilder, the renowned economist and co-founder of the Discovery Institute, Dr. Ricardo Gil-da-Costa, the CEO and co-founder of Neuroverse, and two Huawei Seeds for the Future alumni.
So far, Huawei’s Seeds for the Future program has helped nurture more than 2.2 million digital talents in over 150 countries. The company’s ICT Academy can train about 200,000 students each year. In 2021, Huawei announced it had already invested US$150 million and planned invest another US$150 million in digital talent development before 2026, which is expected to benefit an additional 3 million people.
About the Global Alliance for Literacy
Since its launch in 2016, the Global Alliance for Literacy has driven international discourse and guided the agenda for literacy provision globally for those who need it most. The alliance includes 30 countries committed to improving youth and adult literacy. It serves as a platform for its members to discuss progress and challenges together, and to exchange knowledge and good practice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005765/en/
Contact information
Colin Qian
qianzhecheng@huawei.com
+86 18036392250
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
